Genexine
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Genexine is a biopharmaceutical company that researches and develops medicines, including treatments designed to work with the body's immune system, for patients with serious diseases.
Its products and drug candidates are aimed at healthcare providers and patients, and it operates within the broader life-sciences supply chain as a developer of novel therapies. Genexine is listed on KOSDAQ, South Korea's technology and small-cap stock exchange, and is currently in a development-stage phase where it has not yet reached profitability.
Summary is AI-generated and may contain errors · figures from DART filings
Genexine in five facts
What does Genexine do?
Genexine is a biopharmaceutical company that researches and develops medicines, including treatments designed to work with the body's immune system, for patients with serious diseases.
Where is Genexine listed and in which sector?
Genexine (Korean name: 제넥신) trades under KRX code 095700 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Genexine?
Its market capitalisation was US$87.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Genexine's latest annual revenue and operating profit?
For fiscal year 2025, Genexine reported revenue of US$3.5M, an operating loss of US$27.3M and a net loss of US$20.5M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 56.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Small public offering disclosure (equity)Oct 16
- Material event report (rights offering)
Genexine disclosed a private placement (third-party allotment) to raise US$2.23M, about 2.6% of its market value.
Capital raise · Oct 16 - Shareholder register closure / record date setOct 6
- Resolution to convene a general shareholders' meeting (extraordinary meeting)Oct 6
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Genexine reported separate results for FY2025: revenue of US$3.24M (+60% year on year), an operating loss of US$24.9M and a net loss of US$18.6M.
Earnings · Feb 2